Table III.
Antitumor activity of DHA-dFdC at 1 × RD-MTD, ¾ × RD-MTD, and ½ × RD-MTD in mice with syngeneic L1210 leukemia cells. Data are mean ± S.D. (n = 7).
| Groups | Dose (mg/kg) | Days of treatment | Survival (day) | T/U* | % ILS+ |
|---|---|---|---|---|---|
| Untreated | - | - | 18 | 1.0 | 0 |
| Vehicle | 0 | 1, 4, 8, 11, 14 | 18 | 1.0 | 0 |
| 1 × RD-MTD | 50 | 1, 4, 8, 11, 14 | 26.0 ± 2.3a | 1.4 ± 0.13a | 44.4 |
| 3/4 × RD-MTD | 37.5 | 1, 4, 8, 11, 14 | 22.9 ± 1.2a,b | 1.3 ± 0.07a,b | 27.0 |
| 1/2 × RD-MTD | 25 | 1, 4, 8, 11, 14 | 21.9 ± 1.2a,b | 1.2 ± 0.07a,b | 21.4 |
*
The ratio of the mean survival time of treated group to the median survival time of the untreated group.
+
Increase in life span compared to untreated group. Statistical analysis was performed using one-way ANOVA followed by a Bonferroni post hoc test.
a
p < 0.0001 vs. Control groups (i.e. Untreated and Vehicle);
b
p< 0.0001 vs. 50 mg/kg.